In patients with systemic sclerosis, impaired activity of transforming growth factor β (TGF-β) has a central role in the pathogenesis of fibrosis, which leads to the progression of the disease and severe organ damage. In this context, the authors discuss the mechanisms of aberrant TGF-β signaling and highlight the potential of TGF-β as a therapeutic target in systemic sclerosis.
